

Structural and mechanistic studies of γ -Fe₂O₃ nanoparticle as troxacitabine drug nanocarrier

Neda Mozayeni, Ali Morsali*, Mohammad R. Bozorgmehr, S. Ali Beyramabadi

Department of Chemistry, Mashhad Branch, Islamic Azad University, Mashhad, Iran & Research Center for Animal Development Applied Biology, Mashhad Branch, Islamic Azad University, Mashhad 917568, Iran.

Abstract

Using density functional theory, noncovalent interactions and three mechanisms of covalent functionalization of troxacitabine anticancer drug onto γ -Fe₂O₃ nanoparticles have been investigated. Quantum molecular descriptors of noncovalent configurations were studied. It was specified that binding of troxacitabine onto γ -Fe₂O₃ nanoparticles is thermodynamically suitable. Hardness and the gap of energy between LUMO and HOMO of troxacitabine are higher than the noncovalent configurations, showing the reactivity of troxacitabine increases in the presence of γ -Fe₂O₃ nanoparticles. Troxacitabine can bond to γ -Fe₂O₃ nanoparticles through NH₂ (*k*₁ mechanism), OH (*k*₂ mechanism) and CO (*k*₃ mechanism) groups. The activation energies, the activation enthalpies and the activation Gibbs free energies of these reactions were calculated. It was specified that the *k*₁ and *k*₂ mechanisms are under thermodynamic control and the *k*₃ mechanisms is under kinetic control. These results could be generalized to other similar drugs.

Keywords: γ -Fe₂O₃ nanoparticles, troxacitabine, density functional theory, noncovalent and covalent functionalization, mechanism

INTRODUCTION

One of the nanoscale materials being extensively utilized are magnetic nanoparticles (MNPs) [1-4]. MNPs are made of elements such as iron, nickel, cobalt, and their oxides, and many of their applications are related to iron oxide nanoparticle. MNPs show unique magnetic, electronic, and chemical properties, causing them to be used for biological and pharmaceutical researches [5-10]. The large surface to volume ratio provides the possibility of functionalization of different molecules, including the therapeutic agents, to them [11-14].

Although many efforts have been made to overcome cancer through chemotherapy, but unfortunately, the old strategies and approaches produce many side effects such as vomiting, hair loss, cardiotoxicity and breathing troubles in the patients. The higher the dose of anti-cancer drugs prescribed and used, the higher the increase of toxicity in the tissues and immune system of the body [15, 16].

The magnetic properties of MNPs cause them to have numerous applications in connection with the drug delivery and diagnostics and therapeutics. The drug delivery systems, using MNPs as carrier, have been based on the fact that they could be guided to a specific location such as a cancerous tumor by using external magnetic field [17, 18]. After arrival of MNPs at the target site, the drug is released through the enzymatic activity or through changes in pH, temperature, and osmolality [19, 20].

Iron oxide could exist along with different chemical compositions, such as magnetite (Fe₃O₄) and maghemite (γ -Fe₂O₃). Magnetite and maghemite have the utmost usage in biomedical applications. Covalent and noncovalent (hydrogen bonds and van der Waals interactions) functionalizations play a principle role in the drug delivery systems. The possibility of targeted drug delivery causes

reduction of the amount of drugs consumed and consequently the reduction of their side effects [21-23].

Troxacitabine or 4-amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one (TC) is a synthetic L-nucleoside analogue which has antitumor and anticancer activities and is highly effective in the treatment of advanced leukemia [24, 25].

For the development of drug delivery systems by using MNPs, it is necessary to present molecular models for understanding the mechanism of functionalization of the drugs to these nanoparticles in solvents (especially water). Quantum calculations could be of great assistance to the design and analysis of drug delivery systems. The granting of Nobel Prize for chemistry in 2016 for the design and manufacturing of molecular machines, TCable of being used in drug deliverance as well, confirms our statement [26-28].

Address for correspondence: Ali Morsali, Department of Chemistry, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Email: almorsali@yahoo.com, morsali@mshdiau.ac.ir

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Mozayeni, N., Morsali, A., Bozorgmehr, M. R., Beyramabadi, S. A. Structural and mechanistic studies of γ -Fe₂O₃ nanoparticle as troxacitabine drug nanocarrier. Arch Pharma Pract 2019;10(1):31-7.

We have used quantum calculations for analysis of more stable structures and the mechanism of functionalization of troxacitabine drug to γ -Fe₂O₃ nanoparticles. Such calculations could inspire researchers to manufacture new drug delivery systems. In spite of different theoretical studies on MNPs, so far, few studies have been done on the mechanism of functionalization in solution.

COMPUTATIONAL METHOD

All calculations have been done with the B3LYP [29-31] hybrid density functional level using the GAUSSIAN 09 package [32]. The 6-31G(d,p) basis set was used except for Fe where the LANL2DZ basis set was employed with effective core potential (ECP) functions.

The solvent plays a key role in chemical systems explicitly [33-40] or

implicitly. Polarized continuum model (PCM) was used for the consideration of implicit effects of the solvent.[41,42]. For all species, all degrees of freedom were optimized. The transition state obtained was confirmed to have only one imaginary frequency of the Hessian. The zero-point corrections were also considered to obtain activation energy.

RESULTS AND DISCUSSION

Noncovalent functionalization

Troxacitabine (TC) is a nonplanar molecule with NH₂, oH, CO, and F groups as presented in Fig. 1. γ -Fe₂O₃ nanoparticle was modeled using Fe₆(OH)₁₈(H₂O)₆ ring clusters of six-edge sharing octahedra joining via 12 OH groups [43]. The optimized geometries of γ -Fe₂O₃ nanoparticle (MNP) and troxacitabine (TC) in solution phase are presented in Fig. 1.




Fig. 1. Optimized structures of MNP and TC.

The interaction between TC and MNP through NH₂ (MNP/TC1), OH (MNP/TC2), and CO (MNP/TC3) groups was considered in gas and solution phases. These three configurations have been shown in Figures 2-4 (See supporting information for Cartesian coordinates of the calculated structures).

The solvation energies of TC, MNP, and MNP/TC1-3 have been shown in Table 1. The binding energies (ΔE) of TC to MNP in gas and solution phases were calculated using the following equation and presented in Table 1:

$$\Delta E = E_{MNP/TC1-3} - (E_{MNP} + E_{TC}) \quad (1)$$

The calculated solvation energies show that TC solubility increases in the presence of MNP. The calculated binding energies of MNP/TC2 and MNP/TC3 are negative in gas and solution phases. MNP/TC3 is more stable than MNP/CAP2-3 in both phases.

Table 1. Solvation and binding energies of different configurations (kJ mol⁻¹).

Species	Solvation energy	Binding energy	Binding energy
TC	-58.84	Solution phase	Gas phase

MNP	-126.25		
MNP/TC1	-168.78	13.89	-2.41
MNP/TC2	-158.58	-12.94	-39.45
MNP/TC3	-176.56	-37.97	-46.50

Quantum molecular descriptors such as hardness and electrophilicity index could be used to describe chemical reactivity and stability. The global hardness (η) indicates the resistance of one molecule against the change in its electronic structure (Equation 2). Decrease in η causes a decrease in the reactivity and an increase in stability.

$$\eta = (I - A) / 2 \quad (2)$$

where $I = -E_{HOMO}$ and $A = -E_{LUMO}$ are the ionization potential and the electron affinity of the molecule, respectively. Parr defined the electrophilicity index (ω) as follows [44]:

$$\omega = (I + A)^2 / 4\eta \quad (3)$$

Table 2. Quantum molecular descriptors (eV) and binding energies (kJ mol⁻¹) of TC, MNP, and MNP/TC1-3.

Species	E _{HOMO}	E _{LUMO}	E _g	η	ω
Solution phase (water)					
TC	-6.29	-0.80	5.49	2.75	2.28
MNP	-5.58	-4.48	1.10	0.55	22.95
MNP/TC1	-5.62	-4.51	1.10	0.55	23.28
MNP/TC2	-5.63	-4.53	1.10	0.55	23.37
MNP/TC3	-5.67	-4.66	1.00	0.50	26.54
Gas phase					
TC	-6.12	-0.75	5.37	2.69	2.20

MNP	-5.41	-4.36	1.05	0.53	22.68
MNP/TC1	-5.67	-4.61	1.06	0.53	24.84
MNP/TC2	-5.56	-4.56	0.99	0.50	25.79
MNP/TC3	-5.24	-4.13	1.11	0.55	19.84

Table 2 presents the quantum molecular descriptors for TC, MNP, and MNP/TC1-4 in both phases. In this table, E_g (gap of energy between LUMO and HOMO) was also calculated. E_g notably determines a more stable configuration.

According to the data in Table 2, η and E_g related to the TC drug are higher than those of MNP/TC1-3, showing the reactivity of TC increases in the presence of MNP. ω of TC increases in the presence of MNP, showing that TC acts as electron acceptor.




Fig. 2. Optimized structure of MNP/TC1.




Fig. 3. Optimized structure of MNP/TC2.





Fig. 4. Optimized structure of MNP/TC3.

Covalent functionalization

First, we considered MNP/TC1-2 configurations for the investigation of covalent functionalization in solution phase. In these cases, hydroxyl and amino groups in MNP/TC1-2 attack the Fe atom to transfer its proton to surface OH group of MNP. Scheme 1 shows

the mechanism for the formation of covalent bond between TC and MNP. In these mechanisms, reactants MNP/TC1-2 are converted into the products MNPTC1-2/H₂O by losing H₂O.



Scheme 1. k_1 and k_2 mechanisms.




Fig. 5. Optimized structures of MNPTC1/H₂O and MNPTC2/H₂O.




Fig. 6. Optimized structures of TS_{k1} and TS_{k2}.




Fig. 7. Optimized structures of MNPTC3/H₂O and TS_{k3}.

According to the Scheme 1, in these mechanisms surface OH group from Fe₆(OH)₁₈(H₂O)₆ is substituted by NH (O) from drug TC to give product MNPTC1(2)/H₂O. The optimized structures of products MNPTC1-2/H₂O have been shown in Fig. 5. Using reactant MNP/TC1 and product MNPTC1/H₂O, the transition state of k₁ step was optimized which we call TS_{k1} (Fig. 6). The calculated bond lengths for all mechanisms have been shown in Figs. 2, 5 and 6. Relative energies for optimized structures in all pathways have been calculated in Table 3 by considering electronic plus zero-point energy (*E*), enthalpy (*H*) and Gibbs free energy (*G*) of reactants equal to zero. The activation energy (*E_a*), activation enthalpy (ΔH^\ddagger) and activation Gibbs free energy (ΔG^\ddagger) for *k₁* mechanism are 117.83 kJ mol⁻¹, 118.03 kJ mol⁻¹, and 128.52 kJ mol⁻¹, respectively (Table 3). Similar to *k₁* step, using MNP/TC2 and MNPTC2/H₂O, the transition state of *k₂* step (Fig. 6) was obtained which we call TS_{k2}. *E_a*, ΔH^\ddagger and ΔG^\ddagger for *k₂* step are 131.80 kJ mol⁻¹, 133.34 kJ mol⁻¹, and 142.30 kJ mol⁻¹, respectively (Table 3).


The other reaction for the covalent functionalization of TC onto MNT is shown in Scheme 2. In this mechanism, H₂O from Fe₆(OH)₁₈(H₂O)₆ is substituted by C=O group from TC to give product MNPTC3/H₂O. The optimized structures of product MNPTC3/H₂O has been shown in Fig. 7.

Table 3. Relative energies (kJ mol⁻¹) for different species in k₁-k₃ mechanisms.

species	ΔE	ΔH	ΔG
<i>k₁</i> mechanism			
MNP/TC1	0.00	0.00	0.00
TS _{k1}	117.83	118.03	128.52
MNPTC1/H ₂ O	18.94	16.95	26.51
<i>k₂</i> mechanism			
MNP/TC2	0.00	0.00	0.00
TS _{k2}	131.80	133.34	142.30
MNPTC2/H ₂ O	-6.69	-9.58	-4.70
<i>k₃</i> mechanism			

MNP/TC3	0.00	0.00	0.00
TS _{k3}	84.51	86.06	92.88
MNPTC3/H ₂ O	38.96	39.09	41.88

Using MNP/TC3 and MNPTC3/H₂O, the transition state of k_3 step (Fig. 7) was obtained which we call TS_{k3}. E_a , ΔH^\ddagger and ΔG^\ddagger for k_3 step are 84.51 kJ mol⁻¹, 86.06 kJ mol⁻¹ and 92.88 kJ mol⁻¹ (Table 3).



Scheme 2. k_3 Mechanism.

The activation energy for k_3 mechanism is lower than k_1 and k_2 mechanisms by 33.31 kJ mol⁻¹ and 47.29 kJ mol⁻¹, respectively. On the other hand, using absolute energies, product MNPTC2/H₂O (k_2 mechanisms) is more stable than products MNPTC1/H₂O (k_1 mechanisms) and MNPTC3/H₂O (k_3 mechanism) by 52.46 kJ mol⁻¹ and 20.62 kJ mol⁻¹, respectively, so products MNPTC2/H₂O (high activation energies) and MNPTC3/H₂O (low activation energies) are thermodynamic and kinetic products, respectively.

In other words, thermodynamic and kinetic controls act opposite each other. The high energy barriers of k_1 and k_2 mechanisms are related to the proton transfer from OH and NH₂ of drug to OH of the cluster. Different techniques such as using ultrasonic irradiation, helps to increase the contribution of k_1 and k_2 mechanisms and is in favor of thermodynamic control.

CONCLUSION

Three configurations of noncovalent interaction of drug troxacitabine (TC) onto γ -Fe₂O₃ nanoparticles (MNP) were investigated in gas and solution phases. MNPs were modeled using Fe₆(OH)₁₈(H₂O)₆ ring clusters. The binding energies for two configurations in gas and solution phases are negative, so these interactions are energetically favorable. The global hardness and HOMO-LUMO energy gap of TC are higher than MNP/TC1-3, showing the reactivity of the TC increases in the presence of γ -Fe₂O₃ nanoparticles.

Three mechanisms of covalent functionalization of drug TC onto MNP through NH₂ (k_1 mechanism), OH (k_2 mechanism) and C=O (k_3 mechanism) groups have been studied in detail. The activation parameters related to k_1 and k_2 mechanisms are higher than k_3 mechanism. The product of k_2 mechanism is more stable, but the product of k_3 mechanism is formed faster and therefore MNPTC3/H₂O is kinetic product.

ACKNOWLEDGEMENTS

We thank the Research Center for Animal Development Applied Biology for allocation of computer time.

REFERENCES

- Lu, A. H.; Salabas, E. e. L.; Schüth, F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. *Angewandte Chemie International Edition* 2007, 46, 1222-1244.
- Jun, Y.-w.; Seo, J.-w.; Cheon, J. Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences. *Accounts of Chemical Research* 2008, 41, 179-189.
- Lee, S.-H.; Cha, J.; Sim, K.; Lee, J.-K. Efficient removal of arsenic using magnetic multi-granule nanoclusters. *Bulletin of the Korean Chemical Society* 2014, 35, 605-609.
- Goll, D. Magnetism of nanostructured materials for advanced magnetic recording. *International Journal of Materials Research* 2009, 100, 652-662.
- Sadri, F.; Ramazani, A.; Massoudi, A.; Khoobi, M.; Azizkhani, V.; Tarasi, R.; Dolatyari, L.; Min, B.-K. Magnetic CoFe₂O₄ nanoparticles as an efficient catalyst for the oxidation of alcohols to carbonyl compounds in the presence of oxone as an oxidant. *Bull. Korean Chem. Soc* 2014, 35, 2029.
- Dua, P.; Chaudhari, K. N.; Lee, C. H.; Chaudhari, N. K.; Hong, S. W.; Yu, J.-S.; Kim, S.; Lee, D.-k. Evaluation of toxicity and gene expression changes triggered by oxide nanoparticles. *Bulletin of the Korean Chemical Society* 2011, 32, 2051-2057.
- Pankhurst, Q. A.; Connolly, J.; Jones, S. K.; Dobson, J. Applications of magnetic nanoparticles in biomedicine. *Journal of Physics D: Applied Physics* 2003, 36, R167.
- Berry, C. C.; Curtis, A. S. Functionalisation of magnetic nanoparticles for applications in biomedicine. *Journal of Physics D: Applied Physics* 2003, 36, R198.
- Arruebo, M.; Fernández-Pacheco, R.; Ibarra, M. R.; Santamaría, J. Magnetic nanoparticles for drug delivery. *Nano Today* 2007, 2, 22-32.
- Akbarzadeh, A.; Samiei, M.; Davaran, S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. *Nanoscale research letters* 2012, 7, 144.
- Fang, C.; Zhang, M. Multifunctional magnetic nanoparticles for medical imaging applications. *Journal of Materials Chemistry* 2009, 19, 6258-6266.
- Ding, G.-b.; Liu, H.-y.; Wang, Y.; Lü, Y.-y.; Wu, Y.; Guo, Y.; Xu, L. Fabrication of a magnetite nanoparticle-loaded polymeric nanopatform for magnetically guided drug delivery. *Chemical Research in Chinese Universities* 2013, 29, 103-109.
- Xu, J.; Ju, C.; Sheng, J.; Wang, F.; Zhang, Q.; Sun, G.; Sun, M. Synthesis and characterization of magnetic nanoparticles and its application in lipase immobilization. *Bulletin of the Korean Chemical Society* 2013, 34, 2408-2412.
- Zhao, S. Y.; Lee, D.-G.; Kim, C.-W.; Cha, H.-G.; Kim, Y.-H.; Kang, Y.-S. Synthesis of magnetic nanoparticles of Fe₃O₄ and CoFe₂O₄ and their surface modification by surfactant adsorption. *Bulletin of the Korean Chemical Society* 2006, 27, 237-242.
- Pennock, G. D.; Dalton, W. S.; Roeske, W. R.; Appleton, C. P.; Mosley, K.; Plezia, P.; Miller, T. P.; Salmon, S. E. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. *Journal of the National Cancer Institute* 1991, 83, 105-110.
- Lindley, C.; McCune, J. S.; Thomason, T. E.; Lauder, D.; Sauls, A.; Adkins, S.; Sawyer, W. T. Perception of chemotherapy side effects cancer versus noncancer patients. *Cancer practice* 1999, 7, 59-65.
- Mornet, S.; Vasseur, S.; Grasset, F.; Duguet, E. Magnetic nanoparticle design for medical diagnosis and therapy. *Journal of Materials Chemistry* 2004, 14, 2161-2175.
- Ito, A.; Shinkai, M.; Honda, H.; Kobayashi, T. Medical application of functionalized magnetic nanoparticles. *Journal of bioscience and bioengineering* 2005, 100, 1-11.
- Dobson, J. Magnetic nanoparticles for drug delivery. *Drug Development Research* 2006, 67, 55-60.

20. Namdeo, M.; Saxena, S.; Tankhiwale, R.; Bajpai, M.; Mohan, Y.; Bajpai, S. Magnetic nanoparticles for drug delivery applications. *Journal of Nanoscience and Nanotechnology* 2008, 8, 3247-3271.
21. Morais, P.; Garg, V.; Oliveira, A.; Silveira, L.; Santos, J.; Rodrigues, M.; Tedesco, A. In *ISLAME 2008*; Springer: 2009, p 269-275.
22. Hua, M.-Y.; Liu, H.-L.; Yang, H.-W.; Chen, P.-Y.; Tsai, R.-Y.; Huang, C.-Y.; Tseng, I.-C.; Lyu, L.-A.; Ma, C.-C.; Tang, H.-J. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. *Biomaterials* 2011, 32, 516-527.
23. Kempe, H.; Kempe, M. The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. *Biomaterials* 2010, 31, 9499-9510.
24. Vose, J. M.; Panwalkar, A.; Belanger, R.; Coiffier, B.; Baccarani, M.; Gregory, S. A.; Facon, T.; Fanin, R.; Caballero, D.; Ben-Yehuda, D. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. *Leukemia & lymphoma* 2007, 48, 39-45.
25. Giles, F. J.; Cortes, J. E.; Baker, S. D.; Thomas, D. A.; O'Brien, S.; Smith, T. L.; Beran, M.; Bivins, C.; Jolivet, J.; Kantarjian, H. M. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. *Journal of clinical oncology* 2001, 19, 762-771.
26. Zheng, Y. B.; Kiraly, B.; Huang, T. J. Molecular machines drive smart drug delivery. *Nanomedicine* 2010, 5, 1309-1312.
27. Linko, V.; Ora, A.; Kostiaainen, M. A. DNA nanostructures as smart drug-delivery vehicles and molecular devices. *Trends in Biotechnology* 2015, 33, 586-594.
28. Szymański, W.; Beierle, J. M.; Kistemaker, H. A.; Velema, W. A.; Feringa, B. L. Reversible photocontrol of biological systems by the incorporation of molecular photoswitches. *Chemical Reviews* 2013, 113, 6114-6178.
29. Becke, A. D. Density-functional exchange-energy approximation with correct asymptotic behavior. *Physical Review A* 1988, 38, 3098.
30. Becke, A. D. Density-functional thermochemistry. III. The role of exact exchange. *The Journal of Chemical Physics* 1993, 98, 5648-5652.
31. Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Physical Review B* 1988, 37, 785.
32. Frisch, M.; Trucks, G.; Schlegel, H.; Scuseria, G.; Robb, M.; Cheeseman, J.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. G09 Gaussian Inc. Wallingford, CT 2009.
33. Hooman Vahidi, S.; Morsali, A.; Ali Beyramabadi, S. Quantum mechanical study on the mechanism and kinetics of the hydrolysis of organopalladium Complex [Pd (CNN) P (OMe)₃] in low acidity range. *Computational and Theoretical Chemistry* 2012, 994, 41-46.
34. Akbari, A.; Hoseinzade, F.; Morsali, A.; Ali Beyramabadi, S. Quantum mechanical study on the mechanism and kinetics of the *cis*-to-*trans* isomerization of [Pd (C₆H₅)₃ Cl] F₃ I (PH₃)₂. *Inorganica Chimica Acta* 2013, 394, 423-429.
35. Morsali, A.; Hoseinzade, F.; Akbari, A.; Beyramabadi, S. A.; Ghiasi, R. Theoretical Study of Solvent Effects on the *Cis*-to-*Trans* Isomerization of [Pd (C₆H₅)₃ I (PH₃)₂]. *Journal of Solution Chemistry* 2013, 42, 1902-1911.
36. Mohseni, S.; Bakavoli, M.; Morsali, A. Theoretical and experimental studies on the regioselectivity of epoxide ring opening by nucleophiles in nitromethane without any catalyst: nucleophilic-chain attack mechanism. *Progress in Reaction Kinetics and Mechanism* 2014, 39, 89-102.
37. Beyramabadi, S. A.; Eshtiagh-Hosseini, H.; Housaindokht, M. R.; Morsali, A. Mechanism and kinetics of the Wacker process: a quantum mechanical approach. *Organometallics* 2007, 27, 72-79.
38. Gharib, A.; Morsali, A.; Beyramabadi, S.; Chegini, H.; Ardabili, M. N. Quantum mechanical study on the rate determining steps of the reaction between 2-aminopyrimidine with dichloro-[1-methyl-2-(naphthylazo)imidazole] palladium (II) complex. *Progress in Reaction Kinetics and Mechanism* 2014, 39, 354-364.
39. Morsali, A. Mechanism of the Formation of Palladium (II) Maleate Complex: A DFT Approach. *International Journal of Chemical Kinetics* 2015, 47, 73-81.
40. Ardabili, M. N.; Morsali, A.; Beyramabadi, S. A.; Chegini, H.; Gharib, A. Quantum mechanical study of the alkoxide-independent pathway of reductive elimination of C-O from palladium (p-cyanophenyl) neopentoxide complex. *Research on Chemical Intermediates* 2015, 41, 5389-5398.
41. Cammi, R.; Tomasi, J. Remarks on the use of the apparent surface charges (ASC) methods in solvation problems: Iterative versus matrix-inversion procedures and the renormalization of the apparent charges. *Journal of Computational Chemistry* 1995, 16, 1449-1458.
42. Tomasi, J.; Persico, M. Molecular interactions in solution: an overview of methods based on continuous distributions of the solvent. *Chemical Reviews* 1994, 94, 2027-2094.
43. Jayarathne, L.; Ng, W.; Bandara, A.; Vitanage, M.; Dissanayake, C.; Weerasooriya, R. Fabrication of succinic acid- γ -Fe₂O₃ nano core-shells. *Colloids and surfaces* 2012.
44. Parr, R. G.; Szentpaly, L. v.; Liu, S. Electrophilicity index. *Journal of the American Chemical Society* 1999, 121, 1922-1924.